Gilead Sciences is identified as a participant within the broader medical sector.
2 reports, 0 independent
Updated Jun 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences is identified as a participant within the broader medical sector.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet